Results for "Hearing loss"
Conditions Encyclopedia Entry 1776775275
** This encyclopedia entry is about **Mitochondrial Myopathies**, a group of rare genetic disorders affecting the mitochondria, the energy-producing structures within cells. **CONTENT:** ### Overview Mitochondrial Myopathies (MM) are a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells. These disorders are caused by mutations in the mitochondrial DNA, which is responsible for producing energy for the cell. MM can affect various parts of the body, including the muscles, nervous system, and other organs. The symptoms of MM can vary widely depending on the specific type of disorder and the severity of the mutation. Mitochondrial Myopathies are often inherited in an autosomal dominant or maternal pattern, meaning that a single copy of the mutated gene is enough to cause the disorder. In some cases, the disorder can be caused by a new mutation, which is not inherited from either parent. The diagnosis of MM is often challenging, as the symptoms can be similar to those of other conditions. A diagnosis is typically made through a combination of genetic testing, muscle biopsy, and other diagnostic tests. ### History/Background Mitochondrial Myopathies were first described in the 1960s, but it wasn't until the 1980s that the genetic basis of the disorder was understood. In 1988, a team of researchers discovered that a mutation in the mitochondrial DNA was responsible for a specific type of MM. Since then, numerous other mutations have been identified as causing MM. The understanding of MM has improved significantly over the years, and researchers are working to develop new treatments and therapies for the disorder. ### Key Information Mitochondrial Myopathies are a group of disorders that affect the mitochondria, the energy-producing structures within cells. There are several types of MM, including: * **Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS)**: a disorder that affects the brain, muscles, and other organs. * **Myoclonic Epilepsy with Ragged-Red Fibers (MERRF)**: a disorder that affects the brain and muscles. * **Kearns-Sayre Syndrome (KSS)**: a disorder that affects the muscles, heart, and other organs. * **NARP Syndrome (Neuropathy, Ataxia, and Retinitis Pigmentosa)**: a disorder that affects the nervous system, muscles, and eyes. The symptoms of MM can vary widely depending on the specific type of disorder and the severity of the mutation. Common symptoms include: * Muscle weakness and wasting * Fatigue and muscle pain * Numbness or tingling in the hands and feet * Vision loss * Hearing loss * Seizures and epilepsy * Stroke-like episodes ### Significance Mitochondrial Myopathies are a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells. These disorders can have a significant impact on the quality of life for those affected, and can be life-threatening in some cases. Researchers are working to develop new treatments and therapies for MM, including gene therapy and other experimental treatments. **INFOBOX:** - Name: Mitochondrial Myopathies - Type: Genetic disorder - Date: 1960s (first described) - Location: Worldwide - Known For: Rare genetic disorders affecting the mitochondria **TAGS:** Mitochondrial Myopathies, Genetic disorder, Mitochondria, Energy production, Muscle weakness, Fatigue, Numbness, Vision loss, Hearing loss, Seizures, Epilepsy, Stroke-like episodes, Gene therapy, Experimental treatments.
Health & MedicineMeningitis
Meningitis is a life-threatening infection that causes inflammation of the protective membranes covering the brain and spinal cord, leading to severe symptoms and potentially long-term consequences if left untreated.
Health & MedicineConditions Encyclopedia Entry 1775964610
** **Mitochondrial Myopathies** (MMD) are a group of rare genetic disorders characterized by the progressive degeneration of muscle tissue due to mutations in the mitochondrial DNA. **CONTENT:** ## Overview Mitochondrial Myopathies (MMD) are a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells. These disorders are caused by mutations in the mitochondrial DNA, which is responsible for encoding some of the proteins necessary for energy production. MMDs are characterized by the progressive degeneration of muscle tissue, leading to muscle weakness, fatigue, and other systemic symptoms. The symptoms of MMDs can vary widely depending on the specific mutation and the affected individual, but they often include muscle pain, cramping, and weakness, as well as other systemic symptoms such as gastrointestinal problems, hearing loss, and vision problems. MMDs are often inherited in an autosomal dominant pattern, meaning that a single copy of the mutated gene is sufficient to cause the condition. However, some cases may be caused by spontaneous mutations or by mutations in the nuclear DNA, which can be inherited in an autosomal recessive pattern. The diagnosis of MMDs is often challenging, as the symptoms can be nonspecific and may resemble those of other conditions. However, genetic testing can help identify the underlying mutation and confirm the diagnosis. ## History/Background The first reported case of MMD was in 1962, when a family was identified with a mitochondrial myopathy that was later found to be caused by a mutation in the mitochondrial DNA. Since then, numerous cases of MMD have been reported, and the condition has been recognized as a distinct clinical entity. In the 1980s, the first genetic tests for MMD were developed, allowing for the identification of the underlying mutation and the diagnosis of the condition. Today, MMDs are recognized as a group of rare genetic disorders that affect approximately 1 in 5,000 people worldwide. ## Key Information MMDs are caused by mutations in the mitochondrial DNA, which can affect any of the 37 genes that are encoded by this DNA. The most common mutations associated with MMDs include: * **MELAS syndrome**: A condition characterized by muscle weakness, seizures, and other systemic symptoms. * **MERRF syndrome**: A condition characterized by muscle weakness, ataxia, and other systemic symptoms. * **KSS syndrome**: A condition characterized by muscle weakness, ataxia, and other systemic symptoms. * **NARP syndrome**: A condition characterized by muscle weakness, ataxia, and other systemic symptoms. The symptoms of MMDs can vary widely depending on the specific mutation and the affected individual. Common symptoms include: * Muscle weakness and fatigue * Muscle pain and cramping * Gastrointestinal problems * Hearing loss * Vision problems * Ataxia (loss of coordination and balance) ## Significance MMDs are significant because they highlight the importance of mitochondrial function in maintaining muscle tissue and overall health. The study of MMDs has also led to a greater understanding of the role of mitochondrial DNA in human disease and has provided insights into the development of new treatments for these conditions. Furthermore, MMDs are a reminder of the importance of genetic testing in diagnosing and managing rare genetic disorders. **INFOBOX:** - Name: Mitochondrial Myopathies (MMD) - Type: Rare genetic disorder - Date: 1962 (first reported case) - Location: Worldwide - Known For: Progressive degeneration of muscle tissue due to mutations in the mitochondrial DNA **TAGS:** Mitochondrial Myopathies, MMD, Rare genetic disorder, Mitochondrial DNA, Muscle weakness, Fatigue, Gastrointestinal problems, Hearing loss, Vision problems, Ataxia.
Health & MedicineConditions Encyclopedia Entry 1778257099
** A rare genetic disorder characterized by an abnormal accumulation of **lysosomal** storage materials in cells, leading to cellular dysfunction and various systemic complications. **CONTENT** ### Overview **Conditions Encyclopedia Entry 1778257099**, also known as **Mucopolysaccharidosis Type II (MPS II)**, is a rare genetic disorder caused by the deficiency of the enzyme **iduronate-2-sulfatase (I2S)**. This enzyme plays a crucial role in breaking down **glycosaminoglycans (GAGs)**, which are complex carbohydrates found in connective tissue. Without sufficient I2S, GAGs accumulate in cells, leading to cellular dysfunction and various systemic complications. MPS II is a **lysosomal storage disorder**, which means that the abnormal accumulation of storage materials occurs within lysosomes, the cellular organelles responsible for breaking down and recycling cellular waste. This disorder is inherited in an **X-linked recessive** pattern, meaning that it primarily affects males, who have only one X chromosome. Females can be carriers of the mutated gene but are usually asymptomatic or mildly affected. The symptoms of MPS II can vary widely among affected individuals, but common features include developmental delays, **intellectual disability**, **cloudy corneas**, **hearing loss**, and **short stature**. Other complications may include **cardiovascular disease**, **respiratory problems**, and **skeletal abnormalities**. ### History/Background MPS II was first described in 1963 by French physicians Robert Neustein and Jean-Pierre Maroteaux. Since then, numerous studies have been conducted to understand the underlying mechanisms of the disorder and to develop effective treatments. In the 1980s, the first enzyme replacement therapy (ERT) was introduced, which involved administering the deficient enzyme, I2S, to affected individuals. However, this treatment was met with limited success due to the difficulty in delivering the enzyme to the lysosomes. In recent years, advances in gene therapy and ERT have led to the development of more effective treatments for MPS II. These treatments aim to restore the normal function of I2S and reduce the accumulation of GAGs in cells. ### Key Information - **Prevalence:** MPS II is a rare disorder, affecting approximately 1 in 100,000 to 1 in 250,000 individuals worldwide. - **Genetics:** MPS II is caused by mutations in the IDS gene, which encodes the I2S enzyme. - **Symptoms:** Common symptoms include developmental delays, intellectual disability, cloudy corneas, hearing loss, and short stature. - **Complications:** Cardiovascular disease, respiratory problems, and skeletal abnormalities are common complications. - **Treatment:** Enzyme replacement therapy and gene therapy are currently being explored as potential treatments for MPS II. ### Significance MPS II is a significant disorder due to its impact on affected individuals and their families. The disorder highlights the importance of early diagnosis and treatment, as well as the need for continued research into effective treatments. The development of gene therapy and ERT has provided new hope for individuals with MPS II, and ongoing research aims to improve these treatments and ultimately find a cure for this devastating disorder. **INFOBOX** - Name: Mucopolysaccharidosis Type II (MPS II) - Type: Genetic disorder - Date: 1963 (first described) - Location: Worldwide - Known For: Rare genetic disorder characterized by abnormal accumulation of lysosomal storage materials **TAGS:** Mucopolysaccharidosis, Lysosomal storage disorder, Genetic disorder, Enzyme replacement therapy, Gene therapy, Intellectual disability, Cloudy corneas, Hearing loss, Short stature.
Health & MedicineConditions Encyclopedia Entry 1780963685
** **Mitochondrial Myopathies** are a group of rare genetic disorders caused by mutations in the mitochondrial DNA, leading to muscle weakness, fatigue, and other systemic symptoms. ## Overview Mitochondrial myopathies are a heterogeneous group of disorders that affect the mitochondria, the energy-producing structures within cells. These conditions are caused by mutations in the mitochondrial DNA (mtDNA), which is separate from the nuclear DNA found in the cell's nucleus. Mitochondrial myopathies can affect various systems in the body, including the muscles, nervous system, and other organs. The symptoms of mitochondrial myopathies can vary widely, but often include muscle weakness, fatigue, exercise intolerance, and other systemic symptoms. Mitochondrial myopathies are often inherited in an **autosomal dominant** or **maternal inheritance** pattern, meaning that a mutation in one copy of the mtDNA is sufficient to cause the condition. This is because mitochondrial DNA is inherited solely from the mother, and mutations in the mtDNA can be passed down through generations. Mitochondrial myopathies can affect individuals of any age, but symptoms often become apparent during childhood or adolescence. ## History/Background The first descriptions of mitochondrial myopathies date back to the 1960s, when researchers began to recognize the importance of mitochondrial function in cellular energy production. In the 1980s, the discovery of mtDNA mutations led to a greater understanding of the genetic basis of mitochondrial myopathies. Since then, numerous studies have shed light on the molecular mechanisms underlying these conditions, leading to the development of new diagnostic and therapeutic strategies. ## Key Information Mitochondrial myopathies are caused by mutations in the mtDNA, which can lead to impaired energy production in cells. The most common types of mitochondrial myopathies include: * **Myoclonic epilepsy with ragged-red fibers (MERRF)**: characterized by muscle weakness, seizures, and other systemic symptoms. * **Kearns-Sayre syndrome (KSS)**: a rare condition that affects the muscles, nervous system, and other organs. * **Chronic progressive external ophthalmoplegia (CPEO)**: a condition that affects the muscles controlling eye movement. * **Leigh syndrome**: a severe condition that affects the brain, muscles, and other organs. Symptoms of mitochondrial myopathies can vary widely, but often include: * Muscle weakness and fatigue * Exercise intolerance * Numbness or tingling in the hands and feet * Seizures * Vision problems * Hearing loss * Cardiac arrhythmias ## Significance Mitochondrial myopathies are a significant cause of morbidity and mortality worldwide. These conditions can have a profound impact on an individual's quality of life, leading to significant disability and reduced life expectancy. However, advances in diagnostic and therapeutic strategies have improved outcomes for individuals with mitochondrial myopathies. ## INFOBOX: - **Name:** Mitochondrial Myopathies - **Type:** Genetic disorder - **Date:** 1960s (first descriptions) - **Location:** Worldwide - **Known For:** Rare genetic disorders affecting muscle function and energy production ## TAGS: Genetic disorder, Mitochondrial disease, Muscle weakness, Fatigue, Exercise intolerance, Seizures, Vision problems, Hearing loss, Cardiac arrhythmias